About
Pipeline & Research
NEWS & MEDIA
Investors
Careers
Contact Us

Select Page

BeyondSpring Second-Quarter 2020 Financial Results and Business Updates

September 3, 2020

09.03.2020

BeyondSpring Second-Quarter 2020 Financial Results and Business Updates

Search for:

RECENT NEWS ARTICLES

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual Meeting
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual Meeting
BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
BeyondSpring Files 2021 Annual Report on Form 20-F
BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
BeyondSpring Announces Organizational Streamlining
BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

RECENT MEDIA COVERAGE

TD Ameritrade Watch List
Managing Chemotherapy Toxicities for Improved Patient Outcomes
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
Seed Therapeutics blossoms in an $800M deal with Lilly
Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring

WORK WITH US

LifeSci Advisors

Investor Contact
Ashley R. Robinson
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact
Darren Opland, Ph.D.
+1 646-627-8387
darren@lifescicomms.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

Who We Are
Management Team
Scientific Advisors
Board of Directors

PIPELINE & RESEARCH

Pipeline Overview
Plinabulin
Protein Degradation
Other Pipeline
Posters & Publications
Collaboration
Expanded Access Policy

Stock Overview
Events & Presentations
Financials & Filings
Corporate Governance

Job Opportunities

NEWS & MEDIA

Press Releases
Media Coverage

BeyondSprings Inc LinkedIn

BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved. Privacy Notice | Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.Ok Privacy policy